secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2026-06-23T20:14:22+00:00
Accession:  0001437749-26-021442
Event type: other
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen shareholders approve 1M share equity plan increase, re-elect all directors
--------------------------------------------------------------------------------

- Shareholders approved 2017 Equity Incentive Plan amendment adding 1,000,000 ordinary shares to the reserve.
- All seven director nominees elected: Arie Belldegrun, Elizabeth Barrett, Cynthia Butitta, Stuart Holden, James Robinson, Leana Wen, Daniel Wildman.
- Advisory vote on executive compensation approved (25.1M for, 3.2M against).
- PricewaterhouseCoopers LLP ratified as independent auditor for upcoming year (36.8M for).
- Articles of Association amended to align shareholder proposal eligibility with Israeli Companies Law.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000143774926021442/0001437749-26-021442-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000143774926021442/urgn20260622_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-021442

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer